Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 39.84 USD 3.89%
Market Cap: 143m USD
Have any thoughts about
Aligos Therapeutics Inc?
Write Note

Aligos Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aligos Therapeutics Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Aligos Therapeutics Inc
NASDAQ:ALGS
Cash from Financing Activities
$88.3m
CAGR 3-Years
-23%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aligos Therapeutics Inc
Glance View

Market Cap
137.4m USD
Industry
Biotechnology

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-10-16. The firm is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. The company uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. The company is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). The company developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The firm's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

ALGS Intrinsic Value
13.25 USD
Overvaluation 67%
Intrinsic Value
Price

See Also

What is Aligos Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
88.3m USD

Based on the financial report for Dec 31, 2023, Aligos Therapeutics Inc's Cash from Financing Activities amounts to 88.3m USD.

What is Aligos Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-2%

Over the last year, the Cash from Financing Activities growth was 55 105%. The average annual Cash from Financing Activities growth rates for Aligos Therapeutics Inc have been -23% over the past three years , -2% over the past five years .

Back to Top